The mother of all benders
A privilege of this role is that we at the Advanced Manufacturing Growth Centre (AMGC) get to see Australian ideas of all kinds evolve into high-value products and jobs.
Both parties fall short on R&D in 2019 election
If you were thinking of casting your vote in the 2019 federal election on the basis of the innovation policies of the major parties you now have a choice between proven failure and halfhearted and misguided action. As I have argued, the Coalition’s research and innovation policies have been missing in action, with our national…
Austal debuts new unmanned naval vessel designs
The US arm of Australian shipbuilder Austal (ASX: ASB) has displayed a range of catamaran and trimaran unmanned naval vessels for the first time. The company, which builds ferries and naval vessels in Australia, the Phillipines and the US, used the Sea Air Space 2019 expo in Washington DC to unveil its new unmanned surface…
Carr pledges $2 million sodium ion battery pilot plant for Geelong
The federal opposition has pledged $2 million for a pilot sodium ion battery manufacturing plant in Geelong as part of a $57 million electric vehicle policy announced yesterday.
Clean Energy Council acts on Queensland solar rules
The Clean Energy Council has convened an emergency meeting today (Friday) to discuss new Queensland state government rules covering the installation of solar PV systems. The rules, which require licensed electricians to perform mechanical work such as lifting, mounting and fixing unplugged solar panels, threaten jobs on solar farms and in commercial PV installations according…
Manufacturers – train your staff for IoT risks
By Stuart Corner of IoT Australia The Ponemon Institute has called on organisations to conduct, as a matter of urgency, employee training programs on the risks created by IoT devices. Its view comes from the results of a survey sponsored by third party risk management company Shared Assessments in which Ponemon found few companies conducting…
Pharmaxis closer to US approval for its Bronchitol drug
Sydney biotech drug developer and manufacturer, Pharmaxis (ASX: PXS) has secured a positive recommendation from a key US body for the benefits of its flagship Bronchitol drug in the treatment of adult cystic fibrosis. The decision, from the Pulmonary‐Allergy Drugs Advisory Committee (PADAC), supported the approval for the use of the inhaled dry powder for…
SA’s food waste solutions set to drive a new economy
Food waste is global scourge of alarming enormity – worth an estimated $1.6 trillion annually – but South Australia is placed at the forefront of finding new ecological and economic solutions.
Orica booms on explosives, chemicals
Global chemicals, fertilisers and explosives group Orica (ASX: ORI) today announced booming sales and profits for the first half ended 31 March, 2019. The result of Net Profit After Tax (NPAT) of $33 million, and $167 million before individually significant items, was up 35 per cent on the previous corresponding period. Orica managing director Alberto…
LeafCann gets licence to manufacture medical cannabis
LeafCann Manufacturing, a subsidiary of LeafCann Group, has gained a licence from the Australian Office of Drug Control to manufacture medical cannabis.